Gamida Cell Ltd.
Harey Yehuda 54
88 articles with Gamida Cell Ltd.
Gamida Cell Ltd. (Nasdaq: GMDA), a leading cellular and immune therapeutics company, today announced that the underwriters of its recently closed underwritten public offering of 7,000,000 ordinary shares have exercised in full their option to purchase an additional 1,050,000 ordinary shares at the public offering price of $5.00 per share.
Gamida Cell Ltd. announced the pricing of an underwritten public offering of 7,000,000 ordinary shares at a public offering price of $5.00 per share for aggregate gross proceeds of $35 million, before deducting underwriting discounts and commission and estimated offering expenses.
An international, randomized Phase 3 study of omidubicel in patients with hematologic malignancies is currently ongoing, and omidubicel has not yet been approved for marketing in the United States or any other jurisdiction.
Gamida Cell Bolsters Management Team with Appointment of Tracey Lodie, Ph.D., as Chief Scientific Officer
Dr. Lodie will be responsible for setting the scientific strategy, synthetic biology and priorities for Gamida Cell, as well as overseeing translational research for our clinical pipeline.
Gamida Cell Announces Data for Omidubicel Presented at the International Society for Cellular and Gene Therapy 2019 Annual Meeting
Gamida Cell Ltd. announced that two presentations on omidubicel1, an investigational advanced cell therapy in Phase 3 clinical development designed to enhance the life-saving benefits of hematopoietic stem cell transplant, took place at the International Society for Cell and Gene Therapy 2019 Annual Meeting being held in Melbourne, Australia.
Gamida Cell Ltd. announced that its previously scheduled Annual Meeting of Stockholders will be webcast on Tuesday, June 4, 2019, at 10:00 a.m. ET at the offices of the company located at 5 Nahum Heftsadie Street, Givaat Shaul, Jerusalem 91340 Israel.
Announces USAN selection of omidubicel as nonproprietary name for company’s investigational NAM-expanded hematopoietic stem cells (formerly known as NiCord®)
The conference is hosted by Davis Polk and BMO Capital Markets.
Gamida Cell Ltd., a leading cellular and immune therapeutics company, announced that Julian Adams, Ph.D., the company’s chief executive officer, will present an overview of the company at the 18th Annual Needham Healthcare Conference on Tuesday, April 9, 2019, at 10:40 a.m. ET in New York City.
Gamida Cell Ltd. (Nasdaq: GMDA), a leading cellular and immune therapeutics company, today announced the nominations of Shawn Cline Tomasello and Stephen T. Wills to its board of directors.
Recently Presented NAM-NK and NiCord Data at 2019 TCT Annual Meeting Demonstrate Clinical Progress and Potential of Proprietary NAM Expansion Technology
Gamida Cell Announces Immune Reconstitution Data from Completed Phase 1/2 Clinical Study of NiCord® Presented at 2019 TCT Annual Meeting
Data support ongoing Phase 3 study of NiCord in patients with hematologic malignancies
Gamida Cell Presents New Data from Ongoing Phase 1 Study of NAM-NK and Initial Data from Phase 1/2 Study of NiCord® in Severe Aplastic Anemia at 2019 TCT Annual Meeting
Data in severe aplastic anemia support potential of NiCord to treat non-malignant bone marrow failure disorders
Gamida Cell Announces Agreement with Editas Medicine to Evaluate Use of CRISPR Genome Editing Technology in NAM-NK Cells
Through this agreement, the companies aim to discover optimized NAM-NK cells that could be used to improve the treatment of hematologic malignancies and solid tumors.
Gamida Cell Announces Data from NAM-NK and NiCord® Programs to Be Presented at 2019 TCT Annual Meeting
Gamida Cell Ltd. (Nasdaq: GMDA), a leading cellular and immune therapeutics company, today announced that new data from its clinical programs will be presented at the 2019 Transplantation & Cellular Therapy (TCT) Meetings of American Society for Blood and Marrow Transplantation (ASBMT) and Center for International Blood and Marrow Transplant Research (CIBMTR) taking place in Houston, Texas, February 20 - 24.
– Collaboration Aims to Expand the Use of Bone Marrow Transplant to Treat Hematologic Malignancies and Serious Blood Disorders
Patient Enrollment in Phase 3 Study of NiCord® on Track for Completion in Second Half of 2019; Topline Results Expected in First Half of 2020
The Nasdaq indicated that there was a record amount of biotech initial public offerings this year, including some individual record-breakers—Moderna, Allogene Therapeutics and Rubius Therapeutics. The total for the year is around $8.2 billion raised, breaking 2014’s record of $6.5 billion.
Gamida Cell Announces Publication of Phase 1/2 Clinical Data of NiCord® in the Journal of Clinical Oncology
Gamida Cell Ltd. today announced the publication of data from the previously reported, multi-center Phase 1/2 clinical study evaluating the safety and efficacy of NiCord® as a stand-alone, hematopoietic stem cell (bone marrow) transplant in the Journal of Clinical Oncology1,2.
Gamida Cell Ltd. (Nasdaq: GMDA), a leading cellular and immune therapeutics company, today announced that Julian Adams, Ph.D., the company’s chief executive officer, will participate in a fireside chat at the BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference on Wednesday, December 12th at 1:20 p.m. ET in New York, NY.